Document is current
Any future updates will be listed below
-
Authors
Potter, Rachael A.
Moeller, Ida H.
Khan, Sohrab
Haegel, Hélène
Hollenstein, Andreas
Steiner, Guido
Wandel, Christoph
Murphy, Alexander P.
Asher, Damon R.
Palatinsky, Emanuel
Griffin, Danielle A.
Mason, Stefanie
Iannaccone, Susan T.
Zaidman, Craig M.
Rodino-Klapac, Louise R.
- License Information
-
More Information
Article History
Received: 11 June 2024
Accepted: 19 December 2024
First Online: 2 January 2025
Declarations
:
: R.A.P., I.H.M., S.K., D.R.A., E.P., D.A.G., and S.M. are employees of Sarepta Therapeutics and may have stock options. H.H., A.H., G.S., and C.W. are employees of F. Hoffmann-La Roche Ltd and may have stock options. A.P.M. is an employee of Roche Products Ltd and may have stock options. S.T.I. receives research support from industry (Elpida, Novartis, Biogen, Sarepta Therapeutics, PTC Therapeutics, Scholar Rock, FibroGen, RegenxBio, and ReveraGen) and the Department of Defense W81XWH2010293, Parent Project Muscular Dystrophy, and Cure SMA. She has served on medical advisory boards for Novartis, Biogen, Genentech, and Sarepta Therapeutics. She receives partial salary support from the following grants: National Institutes of Health Wellstone Muscular Dystrophy Center P50HD087351, NeuroNEXT U24NS107176, and the Muscular Dystrophy Association. C.M.Z. receives research support from Biogen and Novartis and has served on an advisory board for Sarepta Therapeutics. L.R.R.K. is an employee of Sarepta Therapeutics and may have stock options and is a co-inventor of AAVrh74.MHCK7.SRP-9001-dys technology.
